Are you looking for a clear, visual guide to optimize treatment for men with metastatic castration-resistant prostate cancer (mCRPC)?

This severe form of prostate cancer, which largely affects the bone, requires precise and strategic treatment planning.

Download our free, comprehensive infographic today to gain a clearer understanding of the therapeutic sequencing of radioligand therapies (RLTs). 

This infographic will equip you with essential knowledge to enhance your clinical practice:

• Establish the safety and clinical effectiveness profile of Radium-223 and Lu-177  when used in sequence for mCRPC management.
• Understand how to expand the use of life-prolonging RLTs for advanced mCRPC patients who often have limited treatment choices.
• Be empowered to encourage sequencing therapy in the treatment management of mCRPC patients to achieve potential life-saving benefits.
• Gain confidence in the strategy that Radium-223 and Lu-177 can both be used in mCRPC without significant additive safety concerns.